A study to evaluate the safety and tolerability of AZD7442 in Chinese Adults
Study identifier:D8850C00008
ClinicalTrials.gov identifier:NCT05184062
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A phase II double-blind, Placebo-controlled study to evaluate the safety and tolerability of AZD7442 in Chinese Adults
Medical condition
Coronavirus disease 2019 (COVID-19)
Phase
Phase 2
Healthy volunteers
No
Study drug
600 mg AZD7442 IV, 600mg placebo IV
Sex
All
Actual Enrollment
272
Study type
Interventional
Age
18 Years - n/a
Date
Study Start Date: 03 Dec 2021
Primary Completion Date: 15 Aug 2022
Study Completion Date: 06 May 2023
Study design
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Other
Verification:
Verified 01 Aug 2023 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD7442 co-administration of a single dose of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by intravenous (IV) infusion. | Drug: 600 mg AZD7442 IV Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion. Other Name: AZD7442 |
| Placebo Comparator: Placebo co-administration of a single dose of 600mg placebo by intravenous (IV) infusion. | Drug: 600mg placebo IV Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion. Other Name: Placebo |
